InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions
14 juin 2022 07h30 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, June 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022
10 févr. 2022 07h30 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma
20 déc. 2021 07h30 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Dec. 20, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization...
InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update
10 nov. 2021 07h30 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia., Nov. 10, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization...
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
13 oct. 2021 16h30 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and...
InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production
17 juin 2021 07h30 HE
|
InMed Pharmaceuticals Inc.
5 g/L cannabinoid yield significantly exceeds reported industry yieldsSignificantly reduces the overall cost of rare cannabinoid manufacturingContinued advancement to GMP-ready large-scale batch...
InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference
09 juin 2021 11h30 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based...
InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11th, 2021
04 mai 2021 07h30 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based...
InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa
28 avr. 2021 07h30 HE
|
InMed Pharmaceuticals Inc.
Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 creamAdditional submissions slated for France, Germany, Greece, and Italy over the next several days and...
InMed Pharmaceuticals Announces Voluntary Delisting from TSX
27 avr. 2021 07h30 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:INM) (TSX:IN), a clinical-stage company developing cannabinoid-based...